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Evelien Vancaester,4 Soﬁe De Blauwe,5 Dimitri Hemelsoet,6 Martin Wiesmann,1
Luc Defreyne2
ABSTRACT
Background Postinterventional cerebral hyperdensities
(PCHDs) are a common ﬁnding after endovascular stroke
treatment. There is uncertainty about the extent to which
PCHDs correspond to hemorrhage or contrast staining.
Our aim was to evaluate the use of PCHD density on
immediate postinterventional CT, and PCHD evolution on
follow-up CT for differentiating contrast staining from
hemorrhage after endovascular treatment.
Methods We retrospectively reviewed the imaging data
of 84 patients who underwent endovascular treatment
for acute arterial ischemic stroke in the anterior
circulation and who received an immediate
postinterventional CT, a follow-up CT within 36 h, and a
follow-up MRI within 10 days.
Results PCHDs were seen in 62 of 84 patients in a
total of 130 Alberta Stroke Program Early CT Score
(ASPECTS) areas. A speciﬁcity of 100% to predict
hemorrhage was only seen for PCHDs with densities
<40 HU (for ruling hemorrhage out) and ≥140 HU (for
ruling hemorrhage in), at the cost of a low sensitivity of
1.1% and 2.4%, respectively. Persisting PCHDs
correlated with hemorrhage with a speciﬁcity of 93.3%
and a sensitivity of 62.5%. When follow-up CT was
performed at least 19 h after the ﬁrst CT, persisting
PCHDs correlated with hemorrhage with a speciﬁcity of
100% and a sensitivity of 62.5%.
Conclusions There are no density thresholds for
PCHDs that allow predicting the absence or presence of
hemorrhage with 100% speciﬁcity and acceptable
sensitivity. A CT scan performed at least 19–24 h after
endovascular therapy is the only reliable method to
differentiate contrast staining from hemorrhage.
INTRODUCTION
Endovascular thrombectomy has become a
common treatment option for acute ischemic stroke
caused by occlusion of large cerebral arteries.1
Hyperdense cerebral areas, also known as postinter-
ventional cerebral hyperdensities (PCHDs), are a
common ﬁnding on non-contrast enhanced CT per-
formed shortly after endovascular stroke treatment
and appear in up to 86% of cases.2 PCHDs are
thought to represent various degrees of ischemic
damage to the blood–brain barrier (BBB).2–18
Normally, the BBB is hardly permeable for iodi-
nated contrast agents or red blood cells. However,
ischemic damage and, to some extent, local toxicity
of tissue plasminogen activator may compromise
the integrity of the BBB. As a consequence, contrast
agent and/or red blood cells can ooze into the par-
enchyma in affected areas.19–23 When ischemic
injury is limited to the endothelial cell layer,
PCHDs are thought to represent contrast staining.
When ischemic injury degrades the basal lamina,
however, PCHDs may also be associated with hem-
orrhage. As the main purpose of a postinterven-
tional CT is to rule out hemorrhage, the presence
of PCHD creates a diagnostic conundrum that can
interfere with further patient treatment, such as the
rapid introduction of antiplatelet treatment or the
administration of anticoagulants.24 25
It has been shown that it is possible to distinguish
contrast staining from hemorrhage via MRI or
dual-energy CT.2–5 The availability of dual-energy
CT is limited, however. Conventional CT, on the
other hand, poses problems when it comes to dis-
tinguishing contrast staining from hemorrhage
because of the similar densities of iodine and hem-
orrhage. Some authors have suggested differentiat-
ing hemorrhage from contrast based on whether or
not PCHDs persist after 24 h, or have proposed
certain density thresholds to predict (>90 HU) or
to rule out (<50 HU) underlying hemor-
rhage.10 11 13 14 17 However, consistent and system-
atic MRI data to validate these CT criteria are
lacking.10 11 13 14 17 The aim of this study was
therefore to evaluate the applicability of density
measurements in PCHDs on immediate postinter-
ventional conventional CT and the evolution of
PCHDs on follow-up CT for the distinction
between hemorrhage and contrast staining.
METHODS
Patients
This was a retrospective study performed in two
university hospitals with a stroke unit and extensive
experience in endovascular stroke treatment.
Patients were included who underwent endovascu-
lar stroke treatment for an acute arterial ischemic
stroke in the anterior circulation and who received
(a) a ﬁrst post-interventional CT within 4.5 h after
the procedure, (b) a second follow-up CT within
36 h of the procedure, and (c) an MRI within
10 days of the procedure. Between January 2011
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and September 2015, 84 patients fulﬁlled all the inclusion
criteria.
Image acquisition and analysis
In center A, immediate postinterventional CTwas performed on
a helical 32-slice CT scanner (Aquilion 32, Toshiba) or a helical
256-slice dual-energy CT scanner (Somatom Deﬁnition Flash,
Siemens Healthcare, Erlangen, Germany). Only ﬁve patients
received dual-energy CT examinations, whereas the rest of the
patients received conventional CT examinations. Mixed images
that were treated as conventional monochromatic CT images
were used for analysis of the ﬁve cases with dual-energy CT
scans. The follow-up CT was always performed on a helical
32-slice CT scanner (Aquilion 32). Postinterventional MRI was
performed on one of two 1.5T systems (Avanto, Siemens
Healthcare; Magnetom Symphony, Siemens Healthcare) or on a
3T system (Magnetom Trio, Siemens Healthcare). In center B,
immediate and follow-up CT scans were performed on a
20-slice CT scanner (Somatom Deﬁnition AS, Siemens; Straton
MX P, Siemens. Postinterventional MRI was performed on a
1.5T scanner (Intera, Philips Healthcare, Best, Netherlands) or a
3T scanner (Magnetom Prisma, Siemens).
PCHDs were assessed using the standardized binary Alberta
Stroke Program Early CT Score (ASPECTS) evaluation form
that divides the brain parenchyma into 12 distinct areas.26 The
association between PCHD and hemorrhage was analyzed per
patient and per ASPECTS area. The density of PCHD was mea-
sured within a circular region-of-interest in the densest appear-
ing area of the PCHD. When PCHDs were persisting on
follow-up CT, the density of the persisting PCHD was measured
in the same region-of-interest. Mean HU was used for statistical
analysis.
T2-weighted ﬂuid-attenuated inversion recovery (T2-FLAIR),
T1-weighted SE, T2-weighted TSE, and diffusion weighted
images (DWI) with apparent diffusion coefﬁcient maps were
acquired in all patients. Hemorrhage was assessed using gradient
echo T2*-weighted (GE-T2*) images that were available in 62/
84 patients. When GE-T2*-weighted images were not available
we used low-b images from DWI sequences, which have been
shown to be effective in determining hemorrhage.27
Clinical and imaging data were evaluated retrospectively after
obtaining consent of the respective ethics committees.
Radiological data were analyzed blinded to all clinical data in
randomized order on standard PACS workstations by one
experienced neuroradiologist and two radiologists-in-training
(center A) or by two experienced neuroradiologists (center B). A
reference standard for statistical analysis was established in a
consensus reading.
Imaging deﬁnitions
Postinterventional cerebral hyperdensities (PCHDs)
We have adopted the term introduced by Nikoubashman et al
who deﬁned PCHDs as non-solid visually distinctive parenchy-
mal hyperdense areas diagnosed within 4.5 h after recanalization
on the ﬁrst postinterventional CT, with a surface of at least
0.1 cm3, an increased density of at least 5 HU compared with
the unaffected contralateral side, without space-occupying
effect, and conforming to the grey-white matter boundaries of
normal anatomic structures.14
Transient PCHDs
Transient PCHDs are PCHDs that become iso- or hypodense to
the unaffected contralateral hemisphere on follow-up CT (see
above for timing).
Persisting PCHDs
Persisting PCHDs are PCHDs that are visible on follow-up CT.
Persisting PCHDs which had increased in volume and no longer
respected the boundaries of normal grey-white matter structures
and/or demonstrated space-occupying effect that could not be
attributed to progressive ischemic edema were considered paren-
chymal hematomas (PH) (see deﬁnition below).
Hemorrhagic transformation
Hemorrhagic transformation (HT) was categorized according to
the European Cooperative Acute Stroke Study (ECASS-1)
classiﬁcation.28
Hemorrhagic infarction (HI): petechial hemorrhage without
space-occupying effect, non-solid and respecting borders of
grey and white matter; further subdivided into HI1 (small
petechiae) and HI2 (more conﬂuent petechiae).
Parenchymal hematoma (PH): coagulum with mass effect;
further subdivided into PH1 (<30% of the infarcted area
with mild space-occupying effect) and PH2 (>30% of the
infarcted area with signiﬁcant space-occupying effect).
Statistical analysis
Continuous variables are presented as mean±SD, ordinal vari-
ables as median, and categorical variables as frequencies. Fisher’
exact tests were used whenever χ2 tests were not applicable.
Student’ t tests and Mann–Whitney U tests were used when
applicable after testing for data distribution with a Shapiro Wilk
test. Results with p values with an α level ≤0.05 were deﬁned as
signiﬁcant. Statistical analyses were performed using SPSS V.22
software (IBM, San Jose, California, USA).
RESULTS
Patients, clinical ﬁndings, and outcome
The mean age of the patients was 61.7 years (range 11–
90 years). Forty-six (55%) patients were female. Initial median
National Institute of Health Stroke Scale (NIHSS) and modiﬁed
Rankin Scale (mRS) scores at admission were 15 and 4, respect-
ively. The median mRS score at 3 months was 2. Details on
general clinical characteristics, treatment, imaging acquisition,
and clinical outcome of all patients and patients with and
without PCHD are summarized in online supplementary table
S1. Baseline clinical variables, occluded arteries, endovascular
recanalization methods, and clinical outcome did not differ
between patients with and without PCHD. However, the time
interval between the end of endovascular treatment and the
immediate postinterventional CT was signiﬁcantly shorter in
patients with PCHD than in those without PCHD (p=0.024).
The frequency of HI was signiﬁcantly higher in patients with
PCHD (p=0.017). The occurrence of PH on follow-up
imaging, however, did not differ between the two groups
(p=0.542).
General imaging ﬁndings
PCHDs were seen on immediate postinterventional CT in 62 of
84 (73.8%) patients in a total of 130 ASPECTS areas. PCHDs
were located in the lenticulostriate territory and in the cortex in
79/130 (60.8%) and 51/130 (39.2%) ASPECTS areas, respect-
ively. PCHDs had a mean density of 63.4±17.0 HU (range 39–
140 HU).
On follow-up CT, 36/62 (58%) patients had transient
PCHDs, 8/62 (13%) patients had persisting PCHDs, and 18/62
(29%) patients had a combination of persisting and transient
PCHDs. Transient and persisting PCHDs were seen in a total of
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98/130 (75.4%) and 30/130 (23.1%) ASPECTS areas, respect-
ively. PCHDs in the lenticulostriate area of two patients had
evolved to a PH1 on follow-up CT (2/130 ASPECTS areas;
1.5%). The majority of persisting PCHDs were located in the
lenticulostriate area (21/30; 70%). Persisting PCHDs had a
mean density of 48.3±9.7 HU (range 32–71 HU). Compared
with the immediate postinterventional CT, a mean decrease in
density of 27.0±19.8 HU (range 1–98 HU) was observed.
On follow-up MRI, HT was observed in 37 of 84 (44.0%)
patients in a total of 52 ASPECTS areas. HTwas seen in an area
that was hyperdense on the immediate postinterventional CT in
41/52 (78.8%) ASPECTS areas. There was HI1 in 24 patients in
a total of 27 ASPECTS areas, HI2 in 20 patients in a total of 23
ASPECTS areas, and PH1 in two patients in a total of 2
ASPECTS areas. There were no cases of PH2. The frequency of
HT on MRI performed within 36 h of the procedure and on
MRI performed between 36 h and 10 days did not differ signiﬁ-
cantly (total patient group p>0.999, patients with PCHD
p=0.703, patients without PCHD p=0.411) (ﬁgure 1).
Association between PCHD density and HT
In total, 1008 ASPECTS areas were evaluated in 84 patients. In
the group without HT, the mean PCHD density was 59.6
±14.1 HU (range 39–136 HU). In the group with HT, the mean
PCHD density was 71.6±20.0 HU (range 49–140 HU) for all
forms of HT combined (HI+PH), 71.3±19.4 HU (range 49–
140 HU) for HI, and 77.0±40.0 HU (range 49–105 HU) for
PH. The mean HU value of PCHD with HT compared with
PCHD without HTwas signiﬁcantly higher (p<0.001). Figure 2
illustrates the distribution of PCHD densities for ASPECTS
areas with and without HTon MRI. HU values ≥90 had a sensi-
tivity of 19.5%, a speciﬁcity of 97.8%, a positive predictive
value (PPV) of 80.0%, and a negative predictive value (NPV) of
72.5% for all forms of HT combined (table 1). These values
were similar when only considering HI. When only PH was
considered, speciﬁcity was similar but PPV was extremely low
(10%). HU values <50 had a sensitivity of 24.7%, a speciﬁcity
of 92.9%, a PPV of 88%, and a NPV of 36.8% to predict the
absence of HT. A speciﬁcity of 100% to predict HT could be
achieved only for PCHD densities <40 HU (for ruling out HT)
and ≥140 HU (for detecting HT), each time at the cost of a low
sensitivity of 1.1% and 2.4% respectively.
Association between PCHD evolution and HT
Table 2 correlates the evolution of PCHD on follow-up CTwith
the presence or absence of HT on MRI. As no new cases of PH
had developed between follow-up CT and MRI, this is a correl-
ation between PCHD evolution and the presence or absence of
HI on MRI. HI was more frequent in persisting than in transi-
ent PCHDs (p<0.001). Only a minority of transient PCHDs
showed HI on MRI (15/98; 15.3%) with HI1 in 13/15 and HI2
in 2/15 cases. Persisting PCHDs correlated with HI in the major-
ity of cases (24/30; 80%) with HI1 in 6/24 and HI2 in 18/24
cases. Persisting PCHDs correlated with HI with a sensitivity of
62.5%, a speciﬁcity of 93.3%, a PPV of 80.6%, and a NPV of
85.0%. The mean density of persisting PCHDs was 47.9
±9.9 HU in the group with HI and 50.2±9.0 HU in the group
without HI (p=0.612). Mean time between postinterventional
CT and follow-up CT was signiﬁcantly longer in patients with
persisting PCHDs and HI than in patients with persisting
PCHD without HI (18:21±6:45 h vs 11:34±6:10 h; p=0.003).
When follow-up CT was performed at least 19 h after the ﬁrst
CT, persisting PCHDs correlated with HI with a speciﬁcity of
100% and a sensitivity of 62.5% (see online supplementary
ﬁgure S1; supplementary table S2). No statistically signiﬁcant
difference was observed for the time between the two CTs
between transient PCHDs with HI and transient PCHDs
without HI (p=0.38).
DISCUSSION
When PCHDs are encountered after endovascular stroke treat-
ment, the main concern is the presence of underlying
Figure 1 Persisting postinterventional
cerebral hyperdensity (PCHD) with
hemorrhagic infarction (HI) type
2. PCHD in the left lentiform nucleus
(A) faded away but is still present on
follow-up CT 22 h later (B). MRI shows
conﬂuent petechiae, corresponding to
HI type 2 (C).
Figure 2 Graph correlating the density of postinterventional cerebral
hyperdensity (PCHD) on immediate postinterventional CT with the
presence or absence of hemorrhagic transformation (HT) on MRI. x axis
shows distribution of densities of PCHD in HU units on immediate
postinterventional CT; y axis shows number of Alberta Stroke Program
Early CT Score (ASPECTS) areas. HI, hemorrhagic infarction; PH,
parenchymal hemorrhage.
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hemorrhage. Some authors have advocated the use of density
thresholds to differentiate contrast staining from hemorrhage on
postinterventional CT. Payabvash et al, for instance, reported
that an average attenuation <50 HU (of the most hyperattenuat-
ing component of the PCHD) can safely and effectively be used
to exclude hemorrhage with a speciﬁcity of 100% and a sensi-
tivity of 56%. However, hemorrhage diagnosis was solely based
on follow-up CT ﬁndings in their series.17 In our study we
relied on MRI veriﬁcation instead of follow-up CT for the diag-
nosis of hemorrhage and found that PCHDs with HU values
<50 HU on immediate postinterventional CT ruled out hemor-
rhage with a good speciﬁcity of 97.8% at the cost of a low sensi-
tivity of 27%. A speciﬁcity of 100% for ruling out hemorrhage
was only achieved with HU values <40 HU, which in turn came
with the cost of an extremely low sensitivity of 1.1%, rendering
this cut-off useless in daily clinical practice.
The same problem applies for HU thresholds to detect hem-
orrhage. PCHDs with densities ≥140 HU correlated with HT
with a speciﬁcity of 100% but were associated with a low sensi-
tivity of 2.4%. In a frequently cited landmark study by Yoon
et al10 the authors described an association of 100% between
PCHDs with densities exceeding 90 HU, which persisted on
follow-up CT and HT. However, the authors based their HT
diagnosis on CT without verifying their results with MRI. In
our series, PCHDs with HU values ≥90 correlated with HT
with a high speciﬁcity (97.8%) but a low sensitivity (19.5%).
Our ﬁndings are in accordance with the results of Kim et al
who systematically correlated their CT ﬁndings with MRI and
who reported that HU values >90 poorly predicted HTwith a
sensitivity of 22% and a speciﬁcity of 97%.12
Thus, we could not identify density thresholds for PCHDs
that allowed predicting the presence or absence of HT with a
speciﬁcity of 100% and an acceptable sensitivity.
Many authors have advocated or employed a 24 h cut-off for
the distinction between extravasated contrast agent and hemor-
rhage,7 9 10 13 14 based on the assumption that hemorrhage is
likely to remain in the extravascular space and thus appear
hyperdense even after 24 h while contrast agent is likely to be
resorbed within 24 h.7 9 10 Systematic MRI correlation to valid-
ate this ‘24 h-wash-out’ heuristic is lacking, however.9 10 13–18
In our study, persisting PCHDs were associated with HI with
a speciﬁcity of 93.2% and a sensitivity of 62.5%. False-positive
persisting PCHDs—not associated with HI on MRI—were only
seen when follow-up CT was performed within 19 h after the
ﬁrst CT. When follow-up CT was performed at least 19 h after
the ﬁrst CT, persisting PCHDs were associated with HI with a
speciﬁcity of 100% and sensitivity of 62.5%.
Transient PCHDs, on the other hand, ruled out HI with a
NPV of 80.6%. False negative transient PCHDs—transient
PCHDs associated with HI on MRI—could not be avoided
regardless of the timing of imaging, however. Although this
implies that transient PCHDs can never rule out HI with 100%
certainty, it should be noted that the majority of HI seen in tran-
sient PCHDs corresponded with small petechial hemorrhages
(HI1) on MRI that could not have been expected to be seen on
follow-up CT.
In the end it should be stressed that the type of hemorrhage
encountered in persisting PCHDs is not parenchymal hemor-
rhage (which—opposed to PCHD—is space-occupying by deﬁn-
ition) but HI, which has a rather benign natural history.
Whereas parenchymal hemorrhage corresponds to an actual
space-occupying hematoma, HI corresponds to petechial
oozing, which is assumed to be a secondary ischemic phenom-
enon, a result of ischemic damage to the microvasculature pos-
sibly related to reperfusion.29 Prognostically, only the PH2 type
is found to be a signiﬁcant predictor of neurological deterior-
ation and mortality at 3 months whereas HI1, HI2 and PH1 are
not associated with increased morbidity and mortality.28 Hence,
HI that might be encountered in PCHDs may have rather minor
clinical implications in daily clinical care.
Study limitations
Major limitations of our study are the retrospective approach
and the delay between follow-up CT and MRI. Due to the delay
between follow-up CT and MRI, we cannot rule out the possi-
bility that some of the HTobserved on MRI reﬂects delayed HT
that developed between these imaging studies. Nevertheless, our
ﬁndings correlate well with those of Kim et al12 who examined
38 patients with PCHD and who performed MRI within 24 h
after the intervention. Furthermore, no increased frequency of
HTwas observed in patients who received MRI within 36 h of
the intervention compared with those who received MRI
between 36 h and 10 days. This is why we feel conﬁdent that
our ﬁndings prove valid despite this limitation.
CONCLUSIONS
PCHDs are a frequent occurrence after interventional stroke
treatment. No density thresholds exist that allow a reliable dif-
ferentiation between hemorrhage and contrast staining on
immediate postinterventional CT. A follow-up CT performed
19–24 h after endovascular treatment is the only reliable
method to differentiate between the two. In those patients for
whom a more rapid differentiation is required, alternative
Table 1 Predictive value of PCHD with densities ≥90 HU on
immediate postinterventional CT for the final HT diagnosis on MRI












HT (HI+PH) 19.5 97.8 80.0 72.5 73.1
HI 17.9 97.8 77.8 73.1 73.4
PH 50.0 98.9 10.0 99.2 92.3
HI, hemorrhagic infarction; HT, hemorrhagic transformation (HI+PH); NPV, negative
predictive value; PCHD, postinterventional cerebral hyperdensity; PH, parenchymal
hemorrhage; PPV, positive predictive value.
Table 2 Association between the evolution of PCHD on follow-up
CT (rows) and the presence of HT on MRI (columns)
No HT
HT
TotalHI1 HI2 PH1 PH2
No PCHD* 867 8 3 0 0 878
Transient PCHD 83 13 2 0 0 98
Persistent PCHD 6 6 18 0 0 30
PH1 0 0 0 2 0 2
PH2 0 0 0 0 0 0
Total 956 27 23 2 0 1008
*No PCHD refers to the number of ASPECTS areas on immediate postinterventional
CT without PCHD.
ASPECTS, Alberta Stroke Program Early CT Score; HI, hemorrhagic infarction; HT,
hemorrhagic transformation (HI+PH); PCHD, postinterventional cerebral hyperdensity;
PH, parenchymal hemorrhage.
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imaging methods such as dual-energy CT or MRI should be
considered.
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